Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 12;5(1):280-300.
doi: 10.1182/bloodadvances.2020003265.

ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease

Paula D James  1 , Nathan T Connell  2 , Barbara Ameer  3   4 , Jorge Di Paola  5 , Jeroen Eikenboom  6 , Nicolas Giraud  7 , Sandra Haberichter  8 , Vicki Jacobs-Pratt  9 , Barbara Konkle  10   11 , Claire McLintock  12 , Simon McRae  13 , Robert R Montgomery  14 , James S O'Donnell  15 , Nikole Scappe  16 , Robert Sidonio  17 , Veronica H Flood  14   18 , Nedaa Husainat  19 , Mohamad A Kalot  19 , Reem A Mustafa  19
Affiliations

ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease

Paula D James et al. Blood Adv. .

Abstract

Background: von Willebrand disease (VWD) is the most common inherited bleeding disorder known in humans. Accurate and timely diagnosis presents numerous challenges.

Objective: These evidence-based guidelines of the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and other health care professionals in their decisions about VWD diagnosis.

Methods: ASH, ISTH, NHF, and WFH established a multidisciplinary guideline panel that included 4 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Outcomes and Implementation Research Unit at the University of Kansas Medical Center (KUMC) supported the guideline-development process, including performing or updating systematic evidence reviews up to 8 January 2020. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently subject to public comment.

Results: The panel agreed on 11 recommendations.

Conclusions: Key recommendations of these guidelines include the role of bleeding-assessment tools in the assessment of patients suspected of VWD, diagnostic assays and laboratory cutoffs for type 1 and type 2 VWD, how to approach a type 1 VWD patient with normalized levels over time, and the role of genetic testing vs phenotypic assays for types 2B and 2N. Future critical research priorities are also identified.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: Authors were members of the diagnosis guideline panel or members of the systematic review team or both, with the addition of V.H.F. who chaired the management panel. All completed disclosure-of-interest forms, which were reviewed by ASH and are available as supplemental Files 2 and 3.

Figures

Figure 1.
Figure 1.
An overall algorithm addressing the diagnosis of VWD. The numbers in the yellow circles correspond to guideline questions. VWF levels refer to VWF antigen (VWF:Ag) and/or platelet-dependent VWF activity. The algorithm says VWF level 30 to 50 for simplicity; this refers to VWF levels of 0.30 to 0.50 IU/mL, with the caveat that the lower limit of the normal range as determined by the local laboratory should be used if it is <0.50 IU/mL. *Men and children, referred to a hematologist and/or first-degree relative affected with VWD. BS, bleeding score; CBC, complete blood count; DDAVP, desmopressin; FVIII, factor FVIII; FVIII:C, FVIII coagulant activity; PT, prothrombin time; PTT, partial thromboplastin time; r/o, rule out; TT, thrombin time; VWF:CB/Ag, ratio of VWF collagen binding to antigen; VWF:FVIIIB, VWF FVIII binding.
Figure 2.
Figure 2.
An algorithm for the diagnosis of type 2B VWD. GPIb, glycoprotein Ib; RIPA, ristocetin-induced platelet agglutination.
Figure 3.
Figure 3.
An algorithm for the diagnosis of type 2N VWD.
See this image and copyright information in PMC

Comment in

References

    1. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.
    1. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P; Board of Trustees of the Guidelines International Network. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156(7):525-531. - PubMed
    1. Schünemann HJ, Al-Ansary LA, Forland F, et al. ; Board of Trustees of the Guidelines International Network. Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med. 2015;163(7):548-553. - PubMed
    1. Alonso-Coello P, Oxman AD, Moberg J, et al. ; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089. - PubMed
    1. Alonso-Coello P, Schünemann HJ, Moberg J, et al. ; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016. - PubMed